WebJul 4, 2024 · We then studied the safety and tolerability of adding mitomycin C 5 mg/m2 on day 1 to this regimen (olaparib plus ICM). Results: 18 patients with unresectable PDAC were enrolled. The MTD of olaparib plus IC was olaparib 100 mg twice-daily on days 1 and 8. The addition of mitomycin C to this dose level was not tolerated. WebJun 16, 2003 · The authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP) in …
Phase III trial of gemcitabine and carboplatin versus …
WebNov 13, 2024 · In most cases, 2 or more drugs are used at the same time to shrink the cancer. The main drug combination used to treat anal cancer is 5-fluorouracil (5-FU) and mitomycin. The combination of 5-FU and cisplatin can also be used, especially in people who can't get mitomycin or for advanced anal cancer. WebObjective: The objective of our study was to describe survival outcome in 124 patients with unresectable hepatocellular carcinoma treated with triple-drug transcatheter arterial chemoembolization (TACE) using doxorubicin, cisplatin, and mitomycin C using a standardized regimen. chillax twice 歌詞
Degradation and inactivation of antitumor drugs - PubMed
WebSep 18, 2024 · Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications. This activity reviews the indications, action, and contraindications for cisplatinum as a valuable agent in treating malignancy. WebMitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial Summary Background Chemoradiation became the standard of care for anal cancer after the ACT I trial. WebAug 7, 2024 · Several different chemotherapeutic agents, including cisplatin, paclitaxel, 5-FU, and mitomycin, have been explored in combination with RT for MIBC. 96 For cisplatin-ineligible patients, gemcitabine is an acceptable alternative based on a 93% clinical CR rate and 5-year OS and cancer-specific survival of 59% and 89%, respectively, in a pooled ... chil-lax ultra soft lounger